Will Sample Providers have access to all phenotype and genotype data from the PAGRA/GenCoE collaboration, or will they only have access to data from their own project?

Following sequencing, the Sample Providers will receive a copy of the sequence data generated from their own samples, and the raw WGS and agreed phenotype data will be shared with approved PAGRA partners, including Roche, for research and development use (in other words, they will share the data with pharma as well as other researchers the Sample providers wish to share with). Phenotype information may be available for the samples, each containing various levels of detail. These will either be in EGA from the original H3Africa data submission or will be requested from the Sample Provider, and where allowed, submitted as new EGA entries linked to the individual sample subsets and can be requested through the access committee. The GenCoE Leadership will apply for access to phenotype data through the H3Africa DBAC for samples from the H3Africa Biorepositories that will be sequenced. The phenotype data will only be available to GenCoE and the Sample Providers for collaborative projects and will be made available to PAGRA members who are funding the sequence data generation. If another requester would like to receive the phenotype data, they must directly contact either the H3Africa DBAC or the Sample Providers.